Mandate

Vinge advises RusForest in connection with inter alia rights issue

September 24, 2010

RusForest carries out a rights issue amounting to approximately SEK 440 million, proposes authorisation for an issue in kind to enable acquisition of shares in companies within Nord Timber Group and acquires a majority stake in LDK-3, both companies with operations in the city of Arkhangelsk in North West Russia.

The rights issue and in kind authorisation are subject to resolutions at an extraordinary general meeting to be held on 8 October 2010 and the LDK-3 acquisition is contingent on inter alia Russian anti-monopoly approval, which is expected to be attained before the end of the year. The transactions are prompted by a capital need to facilitate the development of RusForest’s existing operations in Ust Ilimsk, Magistralny and Boguchany as well as enable RusForest’s expansion into North West Russia, which are central steps in RusForest’s development plan to become Russia’s leading independent forestry and sawmilling company.

Vinge has assisted RusForest in questions relating to Swedish law and Vinge’s team has primarily consisted of Göran Nyström, Jesper Schönbeck, Dain Nevonen, Jonas Johansson and Christian Granqvist.

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025